MedTrace Logo

Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke

NCT06861426 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 4460

Last updated 2025-03-06

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Ginkgo Diterpene Lactone Meglumine

The specific administration protocol (including time of initiation, dosage, and treatment duration) should be strictly adhered to as per the physician's prescription and meticulously documented in the case report forms (CRFs).

Sponsors & Collaborators

  • Ying Gao

    lead OTHER

Principal Investigators

  • Ying Gao, PHD · Dongzhimen Hospital, Beijing

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06861426 on ClinicalTrials.gov